Albireo announces positive results in patients with chronic idiopathic constipation from a Phase IIb trial of A3309
Study met primary and secondary endpoints with both clinical and statistical significance
14-Oct-2010 -
Albireo announced positive top-line results from a Phase IIb study in chronic idiopathic constipation (CIC) assessing efficacy and safety of three different dose levels (5, 10 and 15 mg orally once a day) of the investigational drug A3309 during an eight week trial. Analyses of the data show ...
bases
chronic constipation
inhibitors
+2